Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
May 02, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...
April 25, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
April 08, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and...
March 08, 2024 10:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294...
February 28, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
February 22, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to...
February 15, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
January 31, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
January 09, 2024 09:17 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025 ...